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Historically, hepatitis B virus (HBV) has been con-
sidered species specific and unable to infect baboons. 
Based on this premise, two patients with HBV end-
stage liver disease underwent baboon liver xenotrans-
plantation. To study whether baboons are susceptible 
to HBV infection, four baboons (two receiving immu-
nosuppressive therapy) were inoculated with HBV. 
Animals were followed for 6 months: clinical examina-
tions and biochemical studies were normal, hepatitis 
B surface antigen and hepatitis B core antigen stain-
ing of biopsies was negative, and HBV serology re-
mained negative. HBV polymerase chain reaction was 
transiently positive in one animal, which most likely 
reflects the initial inoculation. This pilot study corrob-
orates historical evidence and beliefs that baboons are 
resistant to HBV. 
Between the 1940s and 1960s, investigators sought a non-
human primate model for hepatitis B by inoculating material 
from patients with clinical hepatitis into various primate 
species (reviewed in 1 and 2). Papio sp (baboons) included in 
this group developed neither clinical nor biochemical signs of 
infection. The sophistication to detect hepatitis B virus 
amV*) antigen (hepatitis B surface antigen [HBsAg]) was 
not available for these studies. Consequently, asymptomatic 
infections could be missed. Previously infected animals 
would not have been detected and their resistance to infec-
tion would have been misinterpreted. When HBV antigens 
and antibodies were identified, a prevalence study including 
99 baboons was performed; all baboons were seronegative for 
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HBV (3). The unsuccessful attempts to induce hepatitis by 
inoculation of infectious material from humans with hepati-
tis coupled with the lack of detectable HBV antigen in this 
large survey of baboons (2, 3) led to the conclusion that 
baboons are resistant to infection with HBY. However, sub-
sequent serologic surveys reported conflicting results, with 
anti-HBsAg found in 4 of7 (4) and 23 of65 (5) baboons. HBV 
screening before two liver xenotransplantations at the Uni-
versity of Pittsburgh found 1 of 31 baboons to have discor-
dant results for anti-HBsAg when tested at two different 
laboratories (6). Accordingly, there has been uncertainty 
about whether baboons are resistant to HBV infection. None 
of these studies used molecular techniques to examine the 
presence of HBV infection. 
Two baboon to human liver xenotransplantations were 
performed at the University of Pittsburgh on patients suffer-
ing from end-stage liver disease secondary to chronic HBV 
infection. The transplant recipients survived 70 and 25 days, 
respectively. Liver biopsy samples and autopsy material of 
the xenograft livers did not show histologic evidence of HBV 
infection and immunohistochemical staining for HBsAg and 
hepatitis B core antigen (HBcAg) was negative (7). Poly-
merase chain reaction (peR) studies were negative for HBV 
in 4 of 5 samples from the xenograft livers (8). The one 
positive sample was ·at the lower limits of detection for the 
assay and was negative on subsequent testing. The positive 
test result on this liver tissue may have reflected the pres-
ence of the patient's peripheral blood lymphocytes (which 
were assayed separately and found to be positive) (8). The 
current pilot study was undertaken to further examine the 
susceptibility of baboons to HBV infection using currently 
available molecular methods. 
METHODS 
Four baboons were inoculated intravenously with 1 ml of a dilu-
tion of infectious serum containing 1Q4·· chimpanzee infectious doses 
of an NIH standardized. dose (gift of Dr. Robert H. Purcell, National 
Institutes of Allergy and Immunology Division, NIH). The specific 
infectivity of this inoculum. had been determined. previously in HBV 
infectivity studies with chimpanzees (9). Two of the four baboons 
were immunosuppressed with oral tacrolimus (FK506), 12 mg/kgI 
day (supplied. by Fujisawa Pharmaceutical Co., Japan). All studies 
were approved. by the Animal Research Committee of Southwest 
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Foundation for Biomedical Research. Animals were fed and watered 
ad libitum and were housed in quarantined facilities. Procedures 
were performed using intramuscular ketamine (10 mglkg) and intra-
muscular diazepam (5 mg) for sedation. Baboons were followed and 
assessed daily for clinical illness. Blood specimena were obtained 
prior to inoculation and then weekly for a complete blood count, liver 
enzyme profile (total bilirubin, aspartate and alanine aminotrana-
ferases, -y-glutamyltransferase), and tacrolimus levels in the animals 
receiving immunosuppression. 
HBV studies. Prior to HBV inoculation, serology was performed 
for HBsAg, anti-HBsAg, anti-HBcAg, hepatitis B early antigen 
(HBeAg), and anti-HBeAg. In addition, total anti-hepatitis A virus 
was evaluated along with antibody againat he'patitis C virus and 
hepatitis delta virus. Repeat HBV serology was performed weekly 
(HBsAg, anti-HBsAg, anti-HBcAg). Weekly serum samples were an-
alyzed by PCR, as described previously (9), to determine whether the 
baboon might support a low level of HBV replication not detected by 
previous methods. 
Liver biopsies. Percutaneous liver biopsies were performed prior 
to HBV inoculation and at 2-month intervals. The tissue specimens 
were routinely fixed in 10% neutral buffered formalin, embedded in 
paraffin, sectioned at 4 /LID, and stained with hematoxylin and eosin. 
For detection of HBcAg and HBsAg with immunocytochemistry, a 
standard avidinlbiotin complex was used with polyclonal primary 
reagents (anti-HBc, rabbit polyclonal, anti-H13s, goat polyclonal; 
DAKO) for 1 hr, followed by the appropriate biotinylated secondary 
antibody, avidinlbiotin complex, and color devEdopment. An irrele-
vant primary antibody was substituted for the primary antibody in 
the negative controls, and known positive tissues were included as 
positive controls. No other special stains were routinely performed 
because the liver biopsy architecture was normal at all times. 
RESULTS and DISCUSSIO:\I 
All animals remained clinically healthy during the 
6-month study. Animals receiving tacrolimus had average 
levels of 0.3 and 0.5 ng/ml, respectively (target level: 0.3-0.7 
nglml). There was no evidence of hepatocellular dysfunction 
nor hematologic abnormalities. HBV DNA and serologic 
studies likewise remained negative on all animals. Liver 
biopsy specimens showed normal hepatic architecture and 
stains for HBcAg and HBsAg were negative. Serum peR 
results were weakly positive on one animal (not immunosup-
pressed) during weeks 2-5. Weekly samples, from weeks 
6-9, following inoculation were all negative on this animaL 
Repeat peR of all samples subsequently failed to detect 
positive reactions on the same sera. The initial positive find-
,ings were at the limits of detection by peR and may repre-
;;;sent transient persistence o~ the inoculum. Delayed clear-
. ance of HBV DNA, as detected by peR, was previously 
reported in macaques (10). 
Although the sample size of this current study is limited, 
the inability to detect HBV infection by peR, liver biopsy 
evaluation, and serology after inoculation of two immuno-
competent baboons and two other immunosuppressed ani-
mals supports the contention that baboons are resistant to 
HBV infection. While consistent with classical World Health 
Organization studies (1) and reports by Deinhardt (2), this 
conclusion is at variance with two reports of seropositivity 
36% (4) and 57% (5) of surveyed baboons. Previously, we 
found only 1 of31 (3%) of baboons to be anti-HBsAg positive 
(6) from the same colony which 14 years earlier had detected 
anti~eBsAg in 51.9% of wild caught baboons and 27.6% of 
colony-raised animals (3). Testing of the one seropositive 
animal by a second laboratory yielded negative results (5). 
Thus, positive serologic tests may have been falsely positive, 
or represent cross-reacting antibody to a related virus. Alter-
natively, the current investigation may have failed to dem-
onstrate transmission because of the small number of 
subjects. The dose of tacrolimus used in the two immunosup-
pressed animals was based on previous studies of immuno-
suppression in baboons (11). However, lymphocyte studies 
were not performed to verify immunosuppression. Nonethe-
less, failure to detect even minimal viral replication using a 
highly sensitive peR assay supports the premise that ba-
boons are in fact resistant to HBV infection. This information 
will be valuable in planning treatment strategies involving 
the use of xenografts. 
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